The Spanish pharmaceutical company Rovi and the Swiss company Roche have agreed that the new drug against obesity and diabetes, currently in an advanced stage of clinical development, will be manufactured in Spain. The agreement, communicated to the CNMV and pending formalization in the coming days, places San Sebastian de los Reyes (Madrid) as the production center for subsequent global distribution.
According to the forecasts submitted by the companies and the Government, the initiative will generate a economic impact exceeding 2.000 billion euros in Spain and will foster the creation of skilled employment. For Rovi, the agreement represents a significant boost to its third-party manufacturing business, with a Sales growth projected at 20%-25% in 2030.
The agreement, in detail
Rovi, through its subsidiary Rois, will make available to Roche a high-speed filling line at its facilities in San Sebastián de los Reyes. Production will be entirely in Spain and the treatment for obesity It will be marketed worldwide once its clinical development is completed and the relevant authorizations are obtained.
- Full production at the plant San Sebastian de los Reyes (Madrid).
- Use of a high-speed filling line for injectables.
- Treatment in advanced clinical development phase.
- Global distribution through Roche's international network.
From Rovi they underline their position as strategic manufacturing partner, the result of years of investment in capabilities and technology focused on injectables. Roche, for its part, strengthens its presence in Spain complete value chain covering research, diagnosis, production and marketing.
Economic and business impact on Rovi
The Executive estimates that the project will boost the economy with more than 2.000 millones de euros between direct and indirect effects, favoring the attraction of investment and the transfer of knowledge. For Rovi, the order will result in a minimum increase of between 20% and 25% of sales from its manufacturing business to third parties by 2030.
In monetary terms, this range is equivalent to a contribution of between 67,2 and 84,5 million euros in 2030, according to the company's estimates. The stock market reacted positively to the announcement, with Rovi shares rising. around 6%.
In addition to the macroeconomic effect, the alliance provides for the creation of qualified employment and the consolidation of high-value industrial infrastructures, strengthening Spain's position in the field of biomedical innovation and the export of advanced therapies.
Institutional support and industrial agenda
The president of the Government, Pedro Sánchez, met in Moncloa with the CEO of Roche, Thomas Schinecker, the president of Rovi, Juan López-Belmonte, and the general manager of Roche Spain, Patrick Wallach. The details of the agreement and its fit with public policies for the promote next-generation pharmaceutical production.
The Executive frames this operation in the Pharmaceutical Industry Strategy 2024-2028 and in the lines of the Recovery, Transformation and Resilience Plan, highlighting public-private collaboration and the attraction of foreign investment as levers to boost the economy and quality employment.
Project status and next steps
The contract is in the final phase and the execution is expected final signature in the next few daysThe drug, which belongs to the metabolic and cardiovascular area Roche's portfolio continues its clinical development with the expectation of being distributed globally once the regulatory procedures have been completed.
With this collaboration, Roche will ensure the future supply of a new therapy for high prevalence diseases, while Rovi capitalizes on the technological capacity of its Madrid plant to scale production with international quality standards.
The alliance between Roche and Rovi places Spain in a strengthened position within the European biopharmaceutical industry: local production of an innovative treatment, global projection, significant economic impact, and a clear roadmap to increase industrial competitiveness and skilled employment in the country.
